Literature DB >> 7580496

Review of cases of nosocomial Lassa fever in Nigeria: the high price of poor medical practice.

S P Fisher-Hoch1, O Tomori, A Nasidi, G I Perez-Oronoz, Y Fakile, L Hutwagner, J B McCormick.   

Abstract

OBJECTIVE: To investigate two hospital outbreaks of Lassa fever in southern central Nigeria.
SETTING: Hospitals and clinics in urban and rural areas of Imo State, Nigeria.
DESIGN: Medical records were reviewed in hospitals and clinics in both areas. Patients with presumed and laboratory confirmed Lassa fever were identified and contracts traced. Hospital staff, patients, and local residents were questioned, records were carefully reviewed, and serum samples were taken. Serum samples were assayed for antibody specific to Lassa virus, and isolates of Lassa virus were obtained.
RESULTS: Among 34 patients with Lassa fever, including 20 patients, six nurses, two surgeons, one physician, and the son of a patient, there were 22 deaths (65% fatality rate). Eleven cases were laboratory confirmed, five by isolation of virus. Most patients had been exposed in hospitals (attack rate in patients in one hospital 55%). Both outbreak hospitals were inadequately equipped and staffed, with poor medical practice. Compelling, indirect evidence revealed that parenteral drug rounds with sharing of syringes, conducted by minimally educated and supervised staff, fuelled the epidemic among patients. Staff were subsequently infected during emergency surgery and while caring for nosocomially infected patients.
CONCLUSION: This outbreak illustrates the high price exacted by the practice of modern medicine, particularly use of parenteral injections and surgery, without due attention to good medical practice. High priority must be given to education of medical staff in developing countries and to guidelines for safe operation of clinics and hospitals. Failure to do so will have far reaching, costly, and ultimately devastating consequences.

Entities:  

Mesh:

Year:  1995        PMID: 7580496      PMCID: PMC2550858          DOI: 10.1136/bmj.311.7009.857

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  10 in total

1.  Inapparent transmission of hepatitis C: footprints in the sand.

Authors:  M J Alter
Journal:  Hepatology       Date:  1991-08       Impact factor: 17.425

2.  Clinical virology of Lassa fever in hospitalized patients.

Authors:  K M Johnson; J B McCormick; P A Webb; E S Smith; L H Elliott; I J King
Journal:  J Infect Dis       Date:  1987-03       Impact factor: 5.226

3.  A case-control study of the clinical diagnosis and course of Lassa fever.

Authors:  J B McCormick; I J King; P A Webb; K M Johnson; R O'Sullivan; E S Smith; S Trippel; T C Tong
Journal:  J Infect Dis       Date:  1987-03       Impact factor: 5.226

4.  Lassa fever antibodies in hospital personnel in the Plateau State of Nigeria.

Authors:  A Fabiyi; O Tomori; P Pinneo
Journal:  Niger Med J       Date:  1979-01

5.  Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings.

Authors:  J D Frame; J M Baldwin; D J Gocke; J M Troup
Journal:  Am J Trop Med Hyg       Date:  1970-07       Impact factor: 2.345

6.  Lassa fever. Epidemiological aspects of the 1970 epidemic, Jos, Nigeria.

Authors:  D E Carey; G E Kemp; H A White; L Pinneo; R F Addy; A L Fom; G Stroh; J Casals; B E Henderson
Journal:  Trans R Soc Trop Med Hyg       Date:  1972       Impact factor: 2.184

7.  Viral hemorrhagic fever antibodies in Nigerian populations.

Authors:  O Tomori; A Fabiyi; A Sorungbe; A Smith; J B McCormick
Journal:  Am J Trop Med Hyg       Date:  1988-03       Impact factor: 2.345

8.  Lassa fever in Onitsha, East Central State, Nigeria in 1974.

Authors:  G S Bowen; O Tomori; H Wulff; J Casals; A Noonan; W G Downs
Journal:  Bull World Health Organ       Date:  1975       Impact factor: 9.408

9.  Acquired immunodeficiency syndrome in Romania.

Authors:  B S Hersh; F Popovici; R C Apetrei; L Zolotusca; N Beldescu; A Calomfirescu; Z Jezek; M J Oxtoby; A Gromyko; D L Heymann
Journal:  Lancet       Date:  1991-09-14       Impact factor: 79.321

10.  A prospective study of the epidemiology and ecology of Lassa fever.

Authors:  J B McCormick; P A Webb; J W Krebs; K M Johnson; E S Smith
Journal:  J Infect Dis       Date:  1987-03       Impact factor: 5.226

  10 in total
  130 in total

1.  Diagnosis and clinical virology of Lassa fever as evaluated by enzyme-linked immunosorbent assay, indirect fluorescent-antibody test, and virus isolation.

Authors:  D G Bausch; P E Rollin; A H Demby; M Coulibaly; J Kanu; A S Conteh; K D Wagoner; L K McMullan; M D Bowen; C J Peters; T G Ksiazek
Journal:  J Clin Microbiol       Date:  2000-07       Impact factor: 5.948

2.  Human dendritic cells infected with the nonpathogenic Mopeia virus induce stronger T-cell responses than those infected with Lassa virus.

Authors:  Delphine Pannetier; Stéphanie Reynard; Marion Russier; Alexandra Journeaux; Noël Tordo; Vincent Deubel; Sylvain Baize
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

Review 3.  Lassa fever: epidemiology, clinical features, and social consequences.

Authors:  J Kay Richmond; Deborah J Baglole
Journal:  BMJ       Date:  2003-11-29

Review 4.  Use of injections in healthcare settings worldwide, 2000: literature review and regional estimates.

Authors:  Yvan J F Hutin; Anja M Hauri; Gregory L Armstrong
Journal:  BMJ       Date:  2003-11-08

5.  Current molecular epidemiology of Lassa virus in Nigeria.

Authors:  Deborah U Ehichioya; Meike Hass; Beate Becker-Ziaja; Jacqueline Ehimuan; Danny A Asogun; Elisabeth Fichet-Calvet; Katja Kleinsteuber; Michaela Lelke; Jan ter Meulen; George O Akpede; Sunday A Omilabu; Stephan Günther; Stephan Olschläger
Journal:  J Clin Microbiol       Date:  2010-12-29       Impact factor: 5.948

6.  Replicon system for Lassa virus.

Authors:  Meike Hass; Uta Gölnitz; Stefanie Müller; Beate Becker-Ziaja; Stephan Günther
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

7.  Characterization of the interaction of lassa fever virus with its cellular receptor alpha-dystroglycan.

Authors:  Stefan Kunz; Jillian M Rojek; Mar Perez; Christina F Spiropoulou; Michael B A Oldstone
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

8.  Genetic variation in vitro and in vivo of an attenuated Lassa vaccine candidate.

Authors:  Juan C Zapata; Marco Goicochea; Yuka Nadai; Lindsay M Eyzaguirre; Jean K Carr; Luke J Tallon; Lisa Sadzewicz; Garry Myers; Claire M Fraser; Qi Su; Mahmoud Djavani; Igor S Lukashevich; Maria S Salvato
Journal:  J Virol       Date:  2013-12-11       Impact factor: 5.103

9.  Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys.

Authors:  Sylvain Baize; Philippe Marianneau; Philippe Loth; Stéphanie Reynard; Alexandra Journeaux; Michèle Chevallier; Noël Tordo; Vincent Deubel; Hugues Contamin
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

10.  Mutational evidence for a structural model of the Lassa virus RNA polymerase domain and identification of two residues, Gly1394 and Asp1395, that are critical for transcription but not replication of the genome.

Authors:  Meike Hass; Michaela Lelke; Carola Busch; Beate Becker-Ziaja; Stephan Günther
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.